Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI

Modern Rheumatology

Volumn 23, Issue 4, 2013, Pages 782-787

  Suzuki, Takeshi ^a   Horikoshi, Masanobu ^a   Sugihara, Makoto ^a   Hirota, Tomoya ^a   Ogishima, Hiroshi ^a   Umeda, Naoto ^a   Kondo, Yuya ^a   Tsuboi, Hiroto ^a   Hayashi, Taichi ^a   Chino, Yusuke ^a   Matsumoto, Isao ^a   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Low field extremity; MRI; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; PREDNISOLONE; TOCILIZUMAB;

ADULT; AGED; ARTICLE; BONE EROSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG EFFICACY; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS; TREATMENT RESPONSE;

EID: 84880797201     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0746-2     Document Type: Article

References (17)

1. Cush JJ. Early rheumatoid arthritis - is there a window of opportunity? J Rheumatol Suppl. 2007;80:1-7.
2. Hyrich KL, Deighton C, Watson KD, BSRBR Control Centre Consortium, Symmons DP, Lunt M. British Society for Rheumatology Biologics Register Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford). 2009;48:1323-7.
3. Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis. 2010;69:126-31.
4. van der Heijde D, Klareskog L, Landewé R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:3928-39.
5. Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. Clin Rheumatol. 2009;28:413-9.
6. Suzuki T, Ito S, Handa S, Kose K, Okamoto Y, Minami M, et al. A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis. Mod Rheumatol. 2009;19:358-65.
7. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-7.
8. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-29.
9. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-23.
10. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
11. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am. 2006;32:9-44, vii.
12. McQueen F, Lassere M, Edmonds J, Conaghan P, Peterfy C, Bird P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Summary of OMERACT 6 MR imaging module. J Rheumatol. 2003;30:1387-92.
13. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011;63:43-52.
14. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54:3761-73.
15. Gandjbakhch F, Conaghan PG, Ejbjerg B, Haavardsholm EA, Foltz V, Brown AK, et al. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol. 2011;38:2039-44.
16. Horikoshi M, Suzuki T, Sugihara M, Kondo Y, Tsuboi H, Uehara T, et al. Comparison of low-field dedicated extremity magnetic resonance imaging with articular ultrasonography in patients with rheumatoid arthritis. Mod Rheumatol. 2010;20:556-60.
17. Suzuki T, Ito S, Handa S, Kose K, Okamoto Y, Minami M, et al. New low-field extremity MRI, compacTscan: comparison with whole-body 1.5 T conventional MRI. Mod Rheumatol. 2010;20:331-6.